March 30, 2005
MDX Medical Inc. Reports First Sales
For Immediate Release
Vancouver, BC, March 30, 2005 - MDX Medical Inc. (TSX.V: MDX) announced today first sales of the AVID technology. The AVID System is available as a fully integrated or software only solution for use by hospitals and clinics which provide Intensity Modulated Radiation Therapy (IMRT) for cancer treatment.
The Swedish Cancer Institute in Seattle, Washington has purchased a fully integrated System comprised of state-of-the-art phantom hardware and the AVID software solution. The Swedish Clinic successfully completed beta testing of the AVID System in late 2004 and is now implementing the AVID System in the first of several clinics as part of their QA standardization initiative.
Dr. Tony Wong, Medical Physicist for the Swedish Cancer Institute earlier stated; "The AVID System offers accurate and qualitative analysis of measured and calculated dose distributions, and all the analysis tools are easy to use. The AVID system is the best IMRT Quality Assurance tool I have used."
The B.C. Cancer Agency, who also completed beta testing of the AVID System, has purchased two licenses for the AVID software for use with their IMRT clinics in the Fraser Valley and Vancouver Center. The AVID software will replace outdated methods and provide enhanced functionality and time savings.
Mark Thomson, President of MDX Medical, states "First sales of the AVID System provide market validation for this remarkable technology and an opportunity for the company to demonstrate our ability to sell the product using an innovative and well-focused marketing strategy". Further, Mark Thomson states "These sales also showcase the flexibility and utility of the technology as a hardware and/or software solution".
MDX Medical recently launched its direct marketing campaign for the AVID software solution, representing a carefully planned and targeted approach to promote the technology. The campaign includes a 30 day, no charge evaluation for medical physicists and is supported by a professional and experienced marketing group.
About MDX Medical
MDX is focused on commercializing innovative and leading-edge medical device technologies for improved diagnosis and treatment of cancer and other life-threatening diseases. The Company's business strategy is to acquire promising technologies that have reached the "proof of feasibility" or later stages of product development, complete the final stages of commercialization, obtain the required regulatory approvals and pursue strategic marketing partners. For more information about MDX, please visit our website at: www.mdxmedical.com.
About Swedish Cancer Institute
The Swedish Cancer Institute is the Northwest's largest cancer care program, offering patients the most extensive range of services and expertise in the region. The Swedish Cancer Institute includes leading cancer specialists, a broad range of treatment options, state of the art facilities and equipment, and cancer care that is as personal as it is progressive and comprehensive.
About BC Cancer Agency
The BC Cancer Agency provides a cancer care program for the people of British Columbia including prevention, screening, early detection, diagnosis and treatment services.
On behalf of the Board,
"Mark Thomson"
President, MDX Medical Inc.
Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Al though the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Larry Horsburgh
Phone: (604) 694-7770, Ext. 112
Email: lhorsburgh@mdxmedical.com
|
